Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
PAQ Therapeutics Raises $39M Series B to Target KRAS-Driven Cancers
Details : The financing aims to fund the clinical development of company's early-stage product PT0253, which is being evaluated for the treatment of neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
May 07, 2025
A Study of PT0253 in Participants With KRAS G12D Mutated Advanced Solid Tumors
Details : PT0253 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 28, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Study Phase : Discovery
Sponsor : Sherpa Healthcare
Deal Size : $30.0 million
Deal Type : Series A Financing
Details : PAQ's novel autophagosome-tethering compounds (ATTECs) are small molecules with the potential to selectively catalyze autophagy-dependent degradation of a wide range of disease-causing substrates.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
July 15, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Highest Development Status : Discovery
Sponsor : Sherpa Healthcare
Deal Size : $30.0 million
Deal Type : Series A Financing
Reset All
